PBR Nachrichten

 

The offer was approved by Assertio's Board of Directors, following a revised merger agreement process and is considered a “superior proposal” compared to the previous agreement with Garda The post Zydus to acquire Assertio in $166m deal appeared first on Pharmaceutical Business review....

The approval covers adults and adolescents in the European Union (EU) who weigh at least 35kg and have haemophilia A (factor VIII deficiency) with factor VIII inhibitors, or The post Pfizer receives EC approval for Hympavzi to treat haemophilia appeared first on Pharmaceutical Business review....

With this authorisation, the UAE is said to become the first nation worldwide to approve this treatment, which is offered in 1mg and 2mg doses. This move underscores The post UAE approves AstraZeneca's Baxfendy for hypertension appeared first on Pharmaceutical Business review....

The round was led by Thrive Capital, with participation from existing investors Alphabet and GV, as well as new investors CapitalG, MGX, Temasek, and the UK Sovereign AI The post Isomorphic Labs receives $2.1bn for AI drug development appeared first on Pharmaceutical Business review....

The move leverages CTTQ's extensive reach and portfolio in liver disease, covering more than 5,000 medical centres in China. Under this agreement, the company will manage the importation, The post GSK and SBP Group team up to advance bepirovirsen launch in China appeared first on Pharmaceutical Business review....

The approval process was accelerated after Partner Therapeutics received the FDA Commissioner's National Priority Voucher. Bizengri has already received breakthrough therapy and orphan drug designations for this indication. The post Partner Therapeutics secures FDA approval for Bizengri appeared first on Pharmaceutical Business review....

The upgrade focuses on providing a unified and accessible framework, eliminating redundant review steps and supporting drug discovery and development projects. With this updated licensing policy, customers have The post ACROBiosystems upgrades HEK293 licence solution for R&D compliance appeared first on Pharmaceutical Business review....

The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy. Sotyktu can be used alone or The post BMS' Sotyktu secures EC approval for psoriatic arthritis appeared first on Pharmaceutical Business review....

The location will serve as Novartis' first RLT manufacturing site in Texas and is the company's fifth such site in the country, increasing supply chain reach for the The post Construction begins on Novartis' RLT centre in Texas, US appeared first on Pharmaceutical Business review....

The acquisition has been approved unanimously by both companies' boards of directors, with the transaction expected to close in the third quarter of 2026. Angelini Pharma will purchase The post Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn appeared first on Pharmaceutical Business review....

Waiv will use its computational pathology platform to work with early phase data, which will involve analysis of tumour microenvironments using haematoxylin and eosin (H&E), as well as The post Daiichi Sankyo and Waiv partner for ADC biomarkers appeared first on Pharmaceutical Business review....

Oruka has licensed the Halozyme technology for use with its lead programme, ORKA-001, which is in development to treat psoriasis and related inflammatory conditions, and up to one The post Halozyme and Oruka sign agreement for Hypercon technology appeared first on Pharmaceutical Business review....

The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic treatment. The The post Citius raises $36.5m for Lymphir commercialisation appeared first on Pharmaceutical Business review....

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. The US Food and The post MSD concludes Terns acquisition to expand CML pipeline appeared first on Pharmaceutical Business review....

Langlara is cleared for use in adults and children with type 1 diabetes mellitus (T1DM), as well as adults with type 2 diabetes mellitus (T2DM). The FDA's decision The post Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara appeared first on Pharmaceutical Business review....

The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures. New The post Latus Bio secures $97m in funding to boost gene therapy access appeared first on Pharmaceutical Business review....

The therapy is approved as an add-on to diet, specifically for adults with FCS whose triglyceride levels remain high despite standard triglyceride-lowering treatments. The approval marks an expansion The post Arrowhead's Redemplo secures Australian TGA approval for FCS therapy appeared first on Pharmaceutical Business review....

The Ozempic oral pill, approved by the Food and Drug Administration (FDA), offers an option for adults with type 2 diabetes to manage blood sugar and cardiovascular risk The post Novo Nordisk to launch Ozempic for type 2 diabetes in US appeared first on Pharmaceutical Business review....

Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. The FDA's decision is based on results from the Phase III ADVANCE-1 The post Axsome receives FDA approval for Auvelity to treat Alzheimer's agitation appeared first on Pharmaceutical Business review....

The acquisition aims to strengthen LEO Pharma's capabilities while leveraging Replay's high payload herpes simplex virus (HSV) delivery vector. It is set to expand LEO Pharma's pipeline in The post LEO Pharma to acquire gene therapy company Replay appeared first on Pharmaceutical Business review....